Probiotics have undergone scientific scrutiny for their potential in reducing the risk of hypertension and they are effective in improving the health conditions among patients with hypertension. Creative Biolabs is committed to providing overall solutions for the discovery and development of next-generation probiotics (NGPs). Our scientists are more than happy to share our experience to facilitate our customers' NGPs project development.
There are many risk factors in developing hypertension, such as sedentary lifestyle, lipid and hypercholesterolemia, chronic inflammation, inconsistent modulation of renin-angiotensin system (RAS), sodium sensitivity, personal habits, anxiety, and stress. There is direct evidence of the factors that control blood pressure (BP), such as a well-programmed nutritional strategy and lifestyle, maintaining recommended body mass index, reduced salt intake, increased potassium intake, and moderation of alcohol intake. The estimated total number of adults with hypertension worldwide during the year 2000 was 1 billion and predicted to rise to 1.58 billion by the year 2025.
Fig.1 Causative agents of hypertension and potential modes of probiotic action on hypertension. (Sudha, 2016)
Dietary strategies have been the focus of the target for repairing the disturbed gut microbiota. Probiotics have been found to decrease systolic/diastolic pressures in prehypertensive and hypertensive patients. Probiotics can low the BP, which is due to a decrease in nitrogen oxide production in macrophages, reducing reactive oxygen species, and enhancing dietary calcium absorption through different mechanisms. These mechanisms are related to the production of short-chain fatty acids (SCFAs), conjugated linoleic acid (CLA), and angiotensin-converting enzyme (ACE) inhibitor peptides. SCFAs, which have a role in both energy metabolism and adipose tissue expansion, also have two sensory receptors that have been linked to BP regulation. Some of the probiotic strains, such as Lactobacillus casei, Streptococcus thermophilus, Lactobacillus plantarum, and Lactobacillus helveticus have been noted to cause a decrease in SBP and can be potentially used in the treatment of hypertension.
At Creative Biolabs, scientists are committed to exploring the potential for the use of probiotics for improving the health conditions in metabolic disorders that increase the risk of developing hypertension. Different strains of probiotics have varying potencies as ACE inhibitory activity based on different bioactive peptides. The effect of the wide variety of probiotic strains can be evaluated in various metabolic disorders to improve the overall health status of the host.
Creative Biolabs is fully competent and dedicated to serving as your one-stop-shop for NGP identification, characterization, and scale-up GMP manufacturing. We offer high-quality custom services by adjusting strategies to meet even the most specific requirements. For more detailed information, please feel free to contact us.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.